CN111235316B - Primer probe for identifying novel coronavirus and application of primer probe in triple fluorescence RPA - Google Patents

Primer probe for identifying novel coronavirus and application of primer probe in triple fluorescence RPA Download PDF

Info

Publication number
CN111235316B
CN111235316B CN202010208673.1A CN202010208673A CN111235316B CN 111235316 B CN111235316 B CN 111235316B CN 202010208673 A CN202010208673 A CN 202010208673A CN 111235316 B CN111235316 B CN 111235316B
Authority
CN
China
Prior art keywords
probe
sars
primer
probes
coronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010208673.1A
Other languages
Chinese (zh)
Other versions
CN111235316A (en
Inventor
吕继洲
张舟
袁向芬
林祥梅
吴绍强
王彩霞
邓俊花
冯春燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinese Academy of Inspection and Quarantine CAIQ
Original Assignee
Chinese Academy of Inspection and Quarantine CAIQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinese Academy of Inspection and Quarantine CAIQ filed Critical Chinese Academy of Inspection and Quarantine CAIQ
Priority to CN202010208673.1A priority Critical patent/CN111235316B/en
Publication of CN111235316A publication Critical patent/CN111235316A/en
Application granted granted Critical
Publication of CN111235316B publication Critical patent/CN111235316B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses a triple RPA primer, a probe, an identification method and an identification kit for rapidly screening and detecting novel coronavirus (SARS-CoV 2) and other SARS coronavirus. The invention designs a first set of primers and probes (marked as FAM) in the N gene sequence region of SARS-CoV2 virus; designing a second set of primers and probes (marked as HEX) in the conserved region E gene sequence of the SARS virus-like virus; a third set of primers and probes (labeled as Cy5, different from other SARS viruses) are designed in the S gene sequence specific region of SARS-CoV2 virus. Compared with the qPCR nucleic acid detection method for definite diagnosis of the novel coronavirus recommended by WHO and national CDC at present, the method has the advantages of high sensitivity, rapidness and effective differentiation of the novel coronavirus and other SARS viruses, can shorten the nucleic acid detection time limit of the virus from 90min to 20min, and can meet the rapid screening requirements of the novel coronavirus and other SARS viruses.

Description

Primer probe for identifying novel coronavirus and application of primer probe in triple fluorescence RPA
Technical Field
The invention belongs to the field of applied biotechnology, and particularly relates to a specific rapid screening detection primer, a probe, an identification method and an identification kit for screening and identifying novel coronavirus and other SARS coronavirus.
Background
Pneumonia epidemic situation (COVID-19) caused by novel coronavirus (SARS-CoV 2) is rolling around the world at present, and has great influence on the normal lives of economy, society and people, and the rapid diagnosis of new coronavirus cases becomes an important means for cutting off the infection source and controlling the spread of the epidemic situation. Especially, the current domestic epidemic situation tends to be stable, the foreign epidemic situation is severe, the number of input disease cases is increased, and the requirement on the accuracy of nucleic acid investigation is higher.
At present, the national CDC and WHO recommend fluorescence quantitative PCR as a novel coronavirus diagnosis method, however, the timeliness is not particularly good in the practical application process, the reverse transcription fluorescence PCR takes 90min, and a special fluorescence PCR instrument is required for data analysis. Compared with fluorescent quantitative PCR, the fluorescent constant-temperature RPA has the advantages of rapidness, accuracy, low requirements on instruments and equipment and the like; in addition, the triple RPA can be used for identifying and distinguishing the novel coronavirus from other SARS viruses, which has great influence on epidemic disease prevention and control and screening other similar epidemic diseases.
Disclosure of Invention
The invention provides a group of primers and probes for identifying a novel coronavirus (SARS-CoV 2), wherein the primers and probes comprise a first set of primer probes, the first set of primer probes comprise a forward primer NF, a reverse primer NR and a probe NP, and the sequences of the primers and probes are as follows:
forward primer NF:
AAGACCTTAAATTCCCTCGAGGACAAGGCGTTC;
reverse primer NR:
AGGTAGTAGAAATACCATCTTGGACTGAGATCT3’;
the probe NP:
CACCAATAGCAGTCCAGATGACCAAATTGGC/i6FAMdT/A/idSp//iBHQ1dT/ACCGAAGAGCTACCAG/iSpC3/。
wherein the fluorescence label of the probe NP is FAM.
Further, the primer and probe set for identifying the novel coronavirus (SARS-CoV 2) further comprises a second set of primer and probe, wherein the second set of primer and probe comprises a forward primer EF, a reverse primer ER and a probe EP, and the sequence of the primer and probe is as follows:
forward primer EF:
GACAGGTACGTTAATAGTTAATAGCGTACTTCT;
reverse primer ER:
AGACTCACGTTAACAATATTGCAGCAGTACGCA;
the probe EP:
TTCGTGGTATTCTTGCTAGTTACACTAGCCA/iHEXdT/C/idSp//iBHQ1dT/TACTGCGCTTCGATTG/iSpC3/;
wherein the fluorescent label of the probe EP is HEX.
Further, the primer and probe set for identifying the novel coronavirus (SARS-CoV 2) further comprises a third set of primer and probe, wherein the third set of primer and probe comprises a forward primer SF, a reverse primer SR and a probe SP, and the sequences of the primer and probe are as follows:
forward primer SF:
AACCATTGGTAGATTTGCCAATAGGTATTAACAT;
reverse primer SR:
CCTAGGTTGAAGATAACCCACATAATAAGCTGC;
and (3) a probe SP:
TACATAGAAGTTATTTGACTCCTGGTGATTCT/iCy5dT/C/idSp//iBHQ2dT/CAGGTTGGACAGCTG/iSpC3/;
the fluorescent label of the probe SP was Cy5.
On the other hand, the invention also provides the application of the primer and the probe in identifying SARS-Cov2 virus and non-SARS-Cov 2 coronavirus.
Further, the application comprises the step of carrying out triple fluorescence RPA reaction on a sample to be detected by using the primer and the probe; if the probe NP, the probe EP and the probe SP are all positive, judging the coronavirus as a novel coronavirus; if the probe EP is positive and the probe NP and the probe SP are negative, the non-SARS-Cov 2 coronavirus is judged; if all of the probe NP, the probe EP and the probe SP are negative, the non-coronavirus is judged.
On the other hand, the invention also provides the application of the primer and the probe in preparing a kit for identifying SARS-Cov2 virus and non-SARS-Cov 2 coronavirus.
Further, the kit is a triple fluorescence RPA reaction kit.
Furthermore, the type of the sample to be detected can be judged according to the reaction result; specifically, if the probe NP, the probe EP, and the probe SP are all positive, the coronavirus is judged to be a novel coronavirus; if the probe EP is positive and the probe NP and the probe SP are negative, the non-SARS-Cov 2 coronavirus is judged; if all of the probe NP, the probe EP, and the probe SP are negative, the sample is judged to be a non-coronavirus.
Further, the non-SARS-Cov 2 coronavirus includes SARS virus and MERS virus.
On the other hand, the invention also provides a specific triple fluorescence RPA kit which can be used for rapidly screening and detecting the novel coronavirus (SARS-Cov 2) and other coronaviruses, wherein the kit comprises an RNA extraction reagent, the primer and the probe.
The primer and the probe for identifying the novel coronavirus (SARS-Cov 2) provided by the invention have low detection sensitivity, can distinguish and identify the novel coronavirus, other SARS viruses except the SARS-Cov2 virus and other non-related pathogens by a triple fluorescence RPA reaction, and have wide application prospect.
Drawings
FIG. 1 shows the first set of primer probes, target N gene, for triple fluorescence RPA detection of novel coronavirus susceptibility test. From left to right, there are 7 wells, 1:10 6 copies/reaction (N gene); 2:10 5 copies/reaction;3:10 4 copies/reaction;4:10 3 copies/reaction;5:10 2 copies/reaction;6:10 1 copies/reaction;7:Negative control。
FIG. 2 shows a second set of primer probes, target E gene, for triple fluorescent RPA detection of novel coronavirus susceptibility assays. From left to right, there are 7 wells, 1:10 6 copies/reaction (E gene); 2:10 5 copies/reaction;3:10 4 copies/reaction;4:10 3 copies/reaction;5:10 2 copies/reaction;6:10 1 copies/reaction;7:Negative control。
FIG. 3 shows the third set of primer probes, target S gene, for triple fluorescence RPA detection of susceptibility of novel coronavirus. From left to right, there are 7 wells, 1:10 6 copies/reaction (S gene); 2:10 5 copies/reaction;3:10 4 copies/reaction;4:10 3 copies/reaction;5:10 2 copies/reaction;6:10 1 copies/reaction;7:Negative control。
FIG. 4, triple fluorescent RPA assay for the detection of novel coronavirus specificity. From left to right, there are 7 wells, 1: PEDV virus nucleic acid; 2: TGEV viral nucleic acid; 3: PPRV viral nucleic acid; 4: FMDV viral nucleic acids; 5: an RV viral nucleic acid; 6: a PPV viral nucleic acid; 7: negative control; 8: positive control (nCov-cDNA).
FIG. 5, triple fluorescent RPA detection of nucleic acids mimicking SARS virus. Three groups were tested simultaneously, positive control, negative control, PEDV. Only the results of nucleic acid detection of the SARS-simulating virus were shown, and the other three groups showed similar results to those in FIG. 4, and were not repeated.
FIG. 6, results of triple fluorescent RPA clinical sample detection (FAM signal, N gene). From left to right, there are 7 wells, 1: clinical samples 2011;2: a clinical specimen 2012;3: clinical specimen 2013;4: clinical sample 2014;5: clinical sample 2015;6: a clinical sample 2016;7: positive control (nCov-cDNA).
FIG. 7, results of triple fluorescent RPA clinical sample detection (HEX signal, E gene). From left to right, there are 7 wells, 1: a clinical specimen 2011;2: a clinical specimen 2012;3: clinical specimen 2013;4: clinical sample 2014;5: clinical sample 2015;6: a clinical sample 2016;7: positive control (nCov-cDNA).
FIG. 8 shows the results of detection of triple fluorescent RPA clinical samples (Cy 5 signal, S gene). From left to right, there are 7 wells, 1: clinical samples 2011;2: a clinical specimen 2012;3: clinical specimen 2013;4: clinical sample 2014;5: clinical sample 2015;6: a clinical sample 2016;7: positive control (nCov-cDNA).
Detailed description of the preferred embodiments
The present invention will be further described with reference to the following examples, which are intended to be illustrative only and not to be limiting of the invention in any way, and any person skilled in the art can modify the present invention by applying the teachings disclosed above and applying them to equivalent embodiments with equivalent modifications. Any simple modification or equivalent changes made to the following embodiments according to the technical essence of the present invention, without departing from the technical spirit of the present invention, fall within the scope of the present invention.
Example 1 acquisition of primer and Probe sequences and construction of Positive plasmids
Comparing and analyzing the full-length nucleic acid sequence of the novel coronavirus (SARS-CoV 2), comparing the full-length nucleic acid sequence with the full-length sequences of SARS virus and SARS-like virus to find out a specific sequence S gene, a virus conserved sequence N gene, a SARS-like virus conserved sequence E gene, an Orf1Ab gene and an M gene of the SARS-CoV2 virus, and designing a primer and a probe according to the sequences; the primers and probes referred to in the present application are shown in the following table:
Figure BDA0002422058250000051
Figure BDA0002422058250000061
the sensitivity test of the fluorescent RPA method is completed by constructing a standard plasmid. Based on the pUC57 plasmid, a target gene is synthesized and a recombinant plasmid is constructed. Transferring into competent cells of Escherichia coli (Escherichia coli) by heat shock method, coating plate to select monoclonal colony, propagating and culturing colony, and extracting plasmid from bacterial liquid. After quantification using Nanodrop, plasmid concentrations were calculated and then diluted to 5 × 10 respectively 6 copies/μl,5×10 5 copies/μl,5×10 4 copies/μl,5×10 3 copies/μl,5×10 2 copies/. Mu.l, 5X 10 copies/. Mu.l, 5 copies/. Mu.l. Can be used for subsequent sensitivity test.
Example 2 treatment of actual test sample and extraction of viral RNA genome
The test sample includes, but is not limited to, human serum, plasma, whole blood, stool, throat swab, sputum, etc. Sample treatment: dissolving 1g of feces or throat swab of 1 patient in 1ml of normal saline, shaking, mixing, centrifuging at 5000r/min for 10min, and collecting supernatant to extract virus RNA. Adding 10g/L acetylcysteine with the same amount into the sputum, shaking for 1h at room temperature, and fully liquefying to extract virus RNA. Anticoagulant (heparin, etc.) should be added to the blood plasma and whole blood.
Extracting virus RNA by a guanidinium isothiocyanate-glass powder method: the specific procedure was (1) to 0.1ml of the sample solution, 0.9ml of guanidinium isocyanate-glass powder lysate (4.7 mol/L guanidinium isothiocyanate, 20mmol/L EDTA,100mmol/L Tris-HCl pH6.4,1% Triton X-100 and 10g glass powder) was added, mixed, and centrifuged at room temperature for 1min and 6 × g for 1min. (2) The supernatant was discarded, and 1ml of a guanidine isothiocyanate rinse (4.7 mol/L guanidine isothiocyanate and 100mmol/L Tris-HCl pH 6.4) was added thereto, followed by mixing and centrifugation at 6000 Xg for 1min. (3) The supernatant was discarded, 1ml of 70% ethanol was added thereto, and the mixture was centrifuged at 6 Xg for 1min. (4) Discarding the supernatant, inverting the plastic centrifuge tube, and baking at 37 ℃ for 10-15 min. (5) Adding 50 mul of DEPC treated deionized water to elute RNA, shaking and mixing uniformly, centrifuging for 1min at 6 Xg, and taking supernatant to be used as a template of fluorescent RPA.
Viral RNA was extracted using QIAGEN's kit (products from other reagents were also used): the operation is carried out according to the instruction, and the specific operation steps are (1) 560 mul of AVL is added into a 1.5ml plastic centrifuge tube, then 140 mul of specimen liquid is added, and the mixture is evenly mixed and acted for 10min at room temperature. And (2) adding 560. Mu.l of absolute ethyl alcohol. (3) Mixing, adding into filter column twice, adding 630 μ l each time, and centrifuging at 8000r/min for 1min. (4) adding 500. Mu.l of AW1 solution, and centrifuging at 8000r/min for 1min. (5) adding 500. Mu.l of AW2 solution, and centrifuging for 3min at 14000 r/min. (6) Finally, 60 mul AVE liquid is added, RNA is eluted at 8000r/min for 1min and is used as a template for PCR amplification.
Example 3 implementation of triple fluorescent RPA
The triple fluorescence RPA reaction comprises 2 steps of preparing a system, amplifying and reading signals. A50 mu L system recommended by an RNA constant-temperature rapid amplification kit (fluorescent type) is adopted, prepared RNA or DNA plasmid is taken as a template, the sequences of the used primers and probes are summarized, and the triple fluorescence RPA reaction is carried out. Fluorescent RPA reaction system (50 μ L): buffer A29.4. Mu.L, forward primers NF, EF, SF 0.8. Mu.L (10. Mu. Mol/L), reverse primers NR, ER, SR 0.8. Mu.L (10. Mu. Mol/L), probes NP, EP, SP 0.3. Mu.L (10. Mu. Mol/L), nucleic acid template 2. Mu.L, RNase-free Water 10.2. Mu.L, ROX dye 0.2. Mu.L, buffer B2.5. Mu.L. The reaction conditions were set as follows: fluorescence signals were collected every 30S for 40 cycles at 42 ℃ for 20 min. The instrument automatically collects fluorescent signals, can observe fluorescent amplification signals in real time, and is a 7500 fluorescent PCR instrument of ABI.
Fluorescence RPA sensitivity test: system of50 μ L, same as in the above system. DNA plasmid template N gene, E gene and S gene of the same concentration 2 uL each (10 times dilution total six concentration gradient, from 5X 10 6 copies/. Mu.l to 5 copies/. Mu.l), negative control RNase-free Water 2. Mu.L.
Fluorescent RPA specificity test: reaction system (50. Mu.L), wherein each viral nucleic acid 2. Mu.L (total nucleic acid amount between 50 and 100 ng). Specific detection includes 6 viruses, two of which are the coronavirus PEDV (porcine epidemic diarrhea virus), TGEV (transmissible gastroenteritis virus), and also the RNA virus PPRV (Peste des petits ruminants virus), the RNA virus FMDV (foot and mouth disease virus), the RNA virus RV (rotavirus) and the DNA virus PPV (porcine parvovirus). The positive control is new coronavirus nucleic acid reverse transcription cDNA, and the negative control is RNase-free water.
The detection distinguishes SARS coronavirus (SARS-Cov) from novel coronavirus (SARS-Cov 2): reaction system (50. Mu.L). Artificially synthesizing the full-length S gene sequence of SARS coronavirus and the full-length N gene of SARS virus, and constructing control plasmids P-SARS-S and P-SARS-N based on pUC57 plasmid. The plasmid P-SARS-S, P-SARS-N and new coronavirus E gene are used as template to simulate SARS virus genome and develop the experiment of triple RPA detection to distinguish new coronavirus and other SARS coronavirus. Four groups are used, wherein positive control is new coronavirus nucleic acid reverse transcription cDNA, negative control is RNase-free water, and other coronavirus PEDV and SARS coronavirus mimic nucleic acid.
And (3) detecting a clinical sample: taking a novel examination and review plan for detecting and measuring the coronavirus nucleic acid in the tissues of the clinical examination centers in Shanghai, and obtaining 6 inactivated clinical samples with the batch numbers of 2011, 2012, 2013, 2014, 2015 and 2016, wherein the sample amount is 600 mu L/sample. The RNA nucleic acid was extracted from a sample of 50. Mu.L/piece in the same manner as described above, and the nucleic acid was dissolved in 20. Mu.L of RNase-free water. The RPA reaction (50. Mu.L) was performed as described above, with 2. Mu.L of nucleic acid in each clinical sample (total amount of nucleic acid between 50 and 100 ng). The positive control is new coronavirus nucleic acid reverse transcription cDNA, and the negative control is RNase-free water.
Example 4, detection results:
the primers and probes referred to in example 1 were tested for sensitivity and specificity. In a triple RPA reaction (requiring three primer probes), the primer probe combinations used were selected as follows:
firstly, the inventor carries out analysis and comparison on five primer probe combinations of NF/NR/NP, NF2/NR2/NP2, ORF/ORR/ORP, ORF2/ORR2/ORP2 and MF/MR/MP, and the combined sensitivity of the primer probe combinations of NF2/NR2/NP2, MF/MR/MP and ORF/ORR/ORP is 10 3 The sensitivity is lower in the order of copies/interaction, and the negative control of the ORF2/ORR2/ORP2 primer probe combination is amplified non-specifically, so that NF/NR/NP is selected as the first set of primer probe in the triple RPA reaction.
Two groups of primer probe combinations are designed aiming at the E gene, and through tests, the analysis sensitivity of the EF2/ER2/EP2 probe combination is low and can only reach 10 4 copies/reaction, so the second set of primer probes for the triple RPA reaction selects EF/ER/EP;
and aiming at the S gene, selecting an SF/SR/SP primer probe combination, and testing the combination to obtain the third set of primer probe SF/SR/SP for the triple RPA reaction, wherein the sensitivity and the specificity of the combination are good.
For the three sets of primer probes (SF/SR/SP, EF/ER/EP and NF/NR/NP) of the selected triple RPA reaction, the sensitivity test of the triple fluorescence RPA detection method shows that the detection limit (sensitivity) of the triple fluorescence RPA detection method to the N gene is 10 2 copies/reaction (FIG. 1), the detection limit (sensitivity) for the E gene was also 10 2 copies/reaction (FIG. 2), the detection limit (sensitivity) for the S gene is within 10copies (FIG. 3). In addition, the specificity of the primer probe is good, the fluorescent RPA method can detect the novel coronavirus, all the genes E, S and N are positive, and no cross reaction is caused with PEDV, TGEV, PPRV, FMDV, RV and PPV (figure 4); detecting SARS coronavirus mimic nucleic acid, the results show that the E gene is positive, and the S gene and N gene are negative (FIG. 5), confirming that the triple RPA detection method can be used for identifying and distinguishing new coronavirus from SARS-like virus; clinical sample testing of triple RPA, N gene test results showed that three samples 2012, 2014 and 2015 were positive (fig. 6), E gene test results also showed that three samples 2012, 2014 and 2015 were positive (fig. 7), while S gene test results showed that four samples 2012, 2014, 2015 and 2016 were positive (fig. 8), with S base in triple RPA methodAnd obtaining a certificate issued by a clinical inspection center organization in Shanghai city because the detection result is in line with 100%.

Claims (6)

1. Primers and probes for identifying a novel coronavirus (SARS-CoV 2), the primers and probes comprising a first set of primer probes, a second set of primer probes and a third set of primer probes,
the first set of primer probes comprises a forward primer NF, a reverse primer NR and a probe NP as follows:
forward primer NF:
AAGACCTTAAATTCCCTCGAGGACAAGGCGTTC;
reverse primer NR:
AGGTAGTAGAAATACCATCTTGGACTGAGATCT3’;
the probe NP:
CACCAATAGCAGTCCAGATGACCAAATTGGC/i6FAMdT/A/idSp//iBHQ1dT/ACCGAAGAGCTACCAG/iSpC3/;
the second set of primer probes comprises a forward primer EF, a reverse primer ER and a probe EP as follows:
forward primer EF:
GACAGGTACGTTAATAGTTAATAGCGTACTTCT;
reverse primer ER:
AGACTCACGTTAACAATATTGCAGCAGTACGCA;
the probe EP:
TTCGTGGTATTCTTGCTAGTTACACTAGCCA/iHEXdT/C/idSp//iBHQ1dT/TACTGCGCTTCGATTG/iSpC3/;
the third set of primer probes comprises a forward primer SF, a reverse primer SR and a probe SP as follows:
forward primer SF:
AACCATTGGTAGATTTGCCAATAGGTATTAACAT;
reverse primer SR:
CCTAGGTTGAAGATAACCCACATAATAAGCTGC;
and (3) a probe SP:
TACATAGAAGTTATTTGACTCCTGGTGATTCT/iCy5dT/C/idSp//iBHQ2dT/CAGGTTGGACAGCTG/iSpC3/。
2. use of the primers and probes for identifying novel coronavirus (SARS-CoV 2) as claimed in claim 1 in the preparation of a kit for identifying SARS-CoV2 virus and non-SARS-CoV 2 coronavirus.
3. The use of claim 2, wherein the virus type of the sample to be tested is judged according to the following reaction results of the kit:
if the probe NP, the probe EP and the probe SP are all positive, judging that the sample to be detected is the novel coronavirus; if the probe EP is positive and the probe NP and the probe SP are negative, judging that the sample to be detected is non-SARS-Cov 2 coronavirus; and if the probe NP, the probe EP and the probe SP are all negative, judging that the sample to be detected is not coronavirus.
4. The use according to claim 2 or 3, wherein the kit is a triple fluorescent RPA reaction kit.
5. A specific triple fluorescent RPA kit for rapid screening and detection of novel coronavirus (SARS-Cov 2) and other coronaviruses, which comprises the primer and probe for identifying novel coronavirus (SARS-CoV 2) as claimed in claim 1.
6. The kit of claim 5, further comprising an RNA extraction reagent.
CN202010208673.1A 2020-03-23 2020-03-23 Primer probe for identifying novel coronavirus and application of primer probe in triple fluorescence RPA Active CN111235316B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010208673.1A CN111235316B (en) 2020-03-23 2020-03-23 Primer probe for identifying novel coronavirus and application of primer probe in triple fluorescence RPA

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010208673.1A CN111235316B (en) 2020-03-23 2020-03-23 Primer probe for identifying novel coronavirus and application of primer probe in triple fluorescence RPA

Publications (2)

Publication Number Publication Date
CN111235316A CN111235316A (en) 2020-06-05
CN111235316B true CN111235316B (en) 2022-11-25

Family

ID=70864549

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010208673.1A Active CN111235316B (en) 2020-03-23 2020-03-23 Primer probe for identifying novel coronavirus and application of primer probe in triple fluorescence RPA

Country Status (1)

Country Link
CN (1) CN111235316B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112094947A (en) * 2020-07-13 2020-12-18 杭州宝临生物科技有限公司 MIA primer, probe, kit and application for detecting new coronavirus
CN111733290A (en) * 2020-07-16 2020-10-02 北京贝尔生物工程股份有限公司 Kit for detecting novel coronavirus and near-field coronavirus and preparation method thereof
CN112239794B (en) * 2020-07-20 2023-12-08 上海伯豪医学检验所有限公司 Primer pair, probe and kit for detecting novel coronavirus SARS-CoV-2 and application thereof
CN112029904A (en) * 2020-08-18 2020-12-04 珠海赛乐奇生物技术股份有限公司 Gene chip and kit for detecting novel coronavirus
CN112029906B (en) * 2020-08-27 2021-06-11 中国检验检疫科学研究院 Two-dimensional code detection method for distinguishing SARS-CoV and SARS-CoV2 virus based on SNP
CN112176106A (en) * 2020-10-13 2021-01-05 华芯生物科技(武汉)有限公司 Primer for detecting respiratory tract pathogenic microorganisms and application thereof
CN112280904A (en) * 2020-11-25 2021-01-29 中国人民解放军军事科学院军事医学研究院 Method for rapidly detecting novel coronavirus nucleic acid
CN112553373A (en) * 2020-12-08 2021-03-26 首都医科大学附属北京朝阳医院 Kit and detection method for quickly detecting novel coronavirus 2019-nCoV nucleic acid
CN112458210B (en) * 2020-12-09 2021-12-10 上海伯杰医疗科技有限公司 Gene conserved sequence, primer probe combination, kit and application for detecting new coronavirus
CN112662811A (en) * 2020-12-25 2021-04-16 北京美康基因科学股份有限公司 Novel coronavirus 4 gene segment multiplex nucleic acid detection kit and application thereof
CN114410835A (en) * 2021-12-02 2022-04-29 华南农业大学 RPA-LFD kit for rapidly detecting novel coronavirus
CN114717363A (en) * 2022-06-09 2022-07-08 中国科学院深圳先进技术研究院 Instant nucleic acid detection method and detection kit for pathogenic mutant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2950618T3 (en) * 2016-03-04 2023-10-11 Abbott Diagnostics Scarborough Inc Device for automated amplification of nested polymerase recombinase

Also Published As

Publication number Publication date
CN111235316A (en) 2020-06-05

Similar Documents

Publication Publication Date Title
CN111235316B (en) Primer probe for identifying novel coronavirus and application of primer probe in triple fluorescence RPA
CN111500776A (en) Novel coronavirus 2019-nCoV fluorescent RPA detection primer, probe, kit and method
CN105441595B (en) It is a kind of for detecting the digital pcr absolute quantitation parting detecting reagent of HBV-B/C
CN111286559B (en) Primer, probe and kit for detecting African swine fever virus
CN109576397B (en) Human immunodeficiency virus type 1 nucleic acid quantitative detection kit
CN105483283B (en) Hepatitis C Virus HCV real-time fluorescence nucleic acid isothermal amplification detection kit
US20220195542A1 (en) Use of primer probe combination and kit thereof in hbv detection
CN110804669A (en) CRISPR (clustered regularly interspaced short palindromic repeats) detection primer group for mycoplasma pneumoniae and application thereof
CN106191311A (en) A kind of quick detection Cavia porcellus LCMV, SV, PVM, Reo 3 virus multiple liquid phase method for gene chip and reagent
CN114015815A (en) Microdroplet digital PCR kit for swine atypical pestivirus and detection method thereof
EP2597162A1 (en) Nucleic acid detection
CN109762932A (en) Identify the detection primer and probe, kit and application of HP-PRRSV and NADC30-like strain
CN111471800B (en) Kit for detecting novel coronavirus and amplification primer composition thereof
CN111676316B (en) Primer, probe and detection method for rapidly distinguishing African swine fever virus gene type II from other genotypes
CN113046483A (en) Novel real-time fluorescent RT-RAA primer, probe and detection kit for coronavirus
CN111500768B (en) Primer probe for identifying novel coronavirus and application of primer probe in dual-digital PCR
CN116814859A (en) Primer probe composition, kit and method for identifying African swine fever virus genes I and II
LU500740B1 (en) REAL-TIME FLUORESCENT PCR DETECTION PRIMERS AND PROBES, KIT AND METHOD FOR NOVEL CORONAVIRUS 2019-nCoV
KR102076343B1 (en) Composition for detecting adenovirus type 55 using Real-time LAMP and uses thereof
CN105567867B (en) Human immunodeficiency virus type 1 real-time fluorescence nucleic acid isothermal amplification detection kit
CN108660252A (en) A kind of human immunodeficiency virus drug resistance analysis method based on pyrosequencing
CN115449563A (en) Multiple fluorescence detection primer probe set and kit for new coronavirus Onckrozen variant strain
CN111206117A (en) Kit for detecting human immunodeficiency virus
CN111575403A (en) High-throughput digital PCR kit for detecting RNA virus nucleic acid and detection method
CN110760596A (en) Clonorchis sinensis liquid drop type digital PCR detection kit and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant